Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company ... A positive CDC decision from the agency will allow Moderna to compete in ...
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first ... older using shared clinical decision-making, meaning seniors ...
Like Spikevax, mRESVIA is based on Moderna's messenger RNA platform. While mRESVIA is not the first RSV vaccine to secure FDA approval—that designation went to GSK's Arexvy—Moderna's offering ...
Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 years of age and older. The Food and Drug Administration (FDA) has ...
Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and older to protect against lower respiratory ...